



Meldola, 02/09/2020

Europass Curriculum Vitae

Personal information

First name(s) / Surname(s) **Laura Mercatali**
E-mail laura.mercatali@irst.emr.it
Nationality Italian

Occupational field **Researcher in translational oncology**

Work experiences

Dates	12/2018→
Occupation or position held	Coordinator of osteoncology Unit, Bioscience lab, ; Lab referent for Osteoncology and rare Tumors; IRST contratto Dirigenti della ricerca, Coordinamento, Fascia A
Main activities and responsibilities	Laboratory biologist. Main activities: paper and grant drafting; coordination of lab researchers activities of CDO-TR together with the director of the Pathology group; Conceiving of translational studies ; Participation to multidisciplinary meetings of CDO-TR; participation to Bioscience Lab meetings on research, and lab management.; lab activities: cell cultures, molecular biology.. Projects topic: translational research in osteoncology and rare tumors, in particular neuro-oncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Type of business or sector	Translational research; Referent for the translational research of CDO-TR team
Dates	09/2015-11/2018
Occupation or position held	Senior Researcher; Lab referent for Osteoncology and rare Tumors; contratto Dirigenti della ricerca, Alta Specializzazione, Fascia A
Main activities and responsibilities	Laboratory biologist. Main activities: paper and grant drafting; coordination of lab researchers activities of CDO-TR together with the director of the Pathology group; Conceiving of translational studies ; Participation to multidisciplinary meetings of CDO-TR; participation to Bioscience Lab meetings on research, and lab management.; lab activities: cell cultures, molecular biology.. Projects topic: translational research in osteoncology and rare tumors, in particular neuro-oncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Type of business or sector	Translational research; Referent for the translational research of CDO-TR team
Dates	01/2008→08/2015
Occupation or position held	Senior Researcher; Lab referent for Osteoncology and rare Tumors
Main activities and responsibilities	Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Coordination of a team of researchers Projects topic: translational research in osteoncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli rd, 47014 Meldola (FC) Italy
Type of business or sector	Translational research and support to clinical diagnostic

Dates	1/2003-12/2007
Occupation or position held	Junior Researcher
Main activities and responsibilities	Laboratory biologist. Main activities: cell cultures, western blot, RT-PCR, RNA and DNA extraction. Article drafting and editing. Conceiving of translational studies. Projects topic: translational research in osteoncology
Name and address of employer	Osteoncology and rare Tumors center, IRCCS Istituto scientifico romagnolo per lo studio e la cura dei tumori (IRST), 40, Piero Maroncelli 47014 Meldola (FC) Italy
Type of business or sector	Translational research and support to clinical diagnostic
Dates	03/2002-12/2002
Occupation or position held	Voluntary worker
Main activities and responsibilities	Laboratory biologist. Main activities: DNA extraction, RT-PCR, database implementation.
Name and address of employer	Bioscience Laboratory, Ospedale Pierantoni, Via Forlanini 34 Forlì (FC), Italy
Type of business or sector	Translational research and support to clinical diagnostic
Education and training	
Dates	2013 jun-set
Type of qualification awarded	VSRC at Princeton University
Principal subjects/occupational skills covered	
Dates	2010→2014
Title of qualification awarded	PHD
Principal subjects/occupational skills covered	Pharmacology, Oncology
Name and type of organisation providing education and training	Alma mater studiorum, Bologna University, Pharmacology Faculty
Dates	2003-2005
Title of qualification awarded	MSC in toxicology (pharmaceutical curriculum) (maximum votation)
Principal subjects/occupational skills covered	Toxicology, Pharmacology, Cancerogenesis process
Name and type of organisation providing education and training	Alma mater studiorum, Bologna University, Pharmacology Faculty
Level in national or international classification	
Dates	2002
Title of qualification awarded	Qualification to the profession of biologist; Registration in the Register "Albo dei Biologi" dal 8/11/2002 (numero d'iscrizione AA_052450)
Dates	10/1996 - 12/2001
Title of qualification awarded	Degree in Biomolecular biology (110/100 e lode)
Principal subjects/occupational skills covered	English language, cellular and molecular biology, Oncology, data analysis,

Name and type of organisation providing education and training	Bologna University, Faculty of Bioscience						
Level in national or international classification	Second level Degree/ Specialistic Degree						
Other language(s)							
Self-assessment							
European level (*)							
English	B2	Independent user	B2	Independent user	B2	Independent user	B2
	(*) Common European Framework of Reference for Languages						
Social skills and competences	Able to work with a group of people on a team, especially in laboratory where is required collaboration between different professional figures						
Technical skills and competences	Good expertise on paper drafting and editing; grant drafting. Good knowledge of laboratory techniques in particular cells cultures, western blot, PCR, DNA and RNA extraction and basic knowledge of cytometry						
Computer skills and competences	Good knowledge of Office packet, in particular word and excel. Basic Knowledge of statistical analysis programs, as SPSS and GraphPad						
Driving licence	Car driving licence						
Honor and award	2012: win a travel grant of 400\$ for an abstract sent to IBCD 2012 (IBMS) 2013: Winner of Francesco Baracca Ward as a I RST researcher 2014: Winner of premio Berlucci Giovani ricercatori 2017: winner of the grant financed by progetto Giovani Ricercatori" GR-2016-02364704 entitled An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT 2019: patent deposited to epo: P n. 19200824.1, under review H index: 21						

Publications

1. Cortesi M, Liverani C, Mercatali L, Ibrahim T, Giordano E. An in-silico study of cancer cell survival and spatial distribution within a 3D microenvironment. Sci Rep. 2020 Jul 31;10(1):12976. doi: 10.1038/s41598-020-69862-7.
2. Bongiovanni A, Mercatali L, Fausti V, Ibrahim T. Comment on 'Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey' by Alice Indini et al. Eur J Cancer. 2020 Jul;134:3-5. doi: 10.1016/j.ejca.2020.04.047.
3. Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, Guercio M, Milano GM, Tamborini E, Busico A, Dagrada G, Garofalo C, Caruso C, Brunello A, Pignochino Y, Berrino E, Grignani G, Scotlandi K, Parra A, Hattinger CM, Ibrahim T, Mercatali L, De Vita A, Carriero MV, Pallocca M, Loria R, Covello R, Sbaraglia M, Dei Tos AP, Falcioni R, Maestro R. Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. Front Oncol. 2020 Apr 15;10:489. doi: 10.3389/fonc.2020.00489.

4. Bongiovanni A, Liverani C, Recine F, Fausti V, Mercatali L, Vagheggini A, Spadazzi C, Miserocchi G, Cocchi C, Di Menna G, De Vita A, Severi S, Nicolini S, Ibrahim T. Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (mNEN): A Systematic Review and Meta-Analysis. *Front Oncol*. 2020 Apr 7;10:414. doi: 10.3389/fonc.2020.00414. eCollection 2020.
5. Cortesi M, Liverani C, Mercatali L, Ibrahim T, Giordano E. Computational models to explore the complexity of the epithelial to mesenchymal transition in cancer. *Wiley Interdiscip Rev Syst Biol Med*. 2020 Mar 24:e1488. doi: 10.1002/wsbm.1488.
6. Recine F, Bongiovanni A, Foca F, Mercatali L, Fausti V, Calpona S, Riva N, De Vita A, Liverani C, Spadazzi C, Miserocchi G, Di Menna G, Gurrieri L, Cocchi C, Debonis SA, Vespignani R, Ibrahim T. BOne HHealth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center "Real-Life" Experience (BOHEME Study). *J Clin Med*. 2019 Nov 6;8(11):1894. doi: 10.3390/jcm8111894.
7. Bongiovanni A, Liverani C, Recine F, Mercatali L, Severi S, Ibrahim T. Comment on the Paper by Lemelin et al. Entitled "Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study". *Neuroendocrinology*. 2020;110(7-8):721-722. doi: 10.1159/000504550.
8. Liverani C, De Vita A, Minardi S, Kang Y, Mercatali L, Amadori D, Bongiovanni A, La Manna F, Ibrahim T, Tasciotti E. A biomimetic 3D model of hypoxia-driven cancer progression. *Sci Rep*. 2019 Aug 22;9(1):12263. doi: 10.1038/s41598-019-48701-4.
9. Bongiovanni A, Recine F, Fausti V, Rossi B, Mercatali L, Liverani C, De Vita A, Gurrieri L, De Bonis S, Miserocchi G, Spadazzi C, Calpona S, Riva N, Cocchi C, Ibrahim T. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: An evidence-based review. *Int J Clin Pract*. 2019 Aug 13:e13404. doi: 10.1111/ijcp.13404
10. Spadazzi C, Recine F, Mercatali L, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Fausti V, Ibrahim T. mTOR inhibitor and bone-targeted drugs break the vicious cycle between clear-cell renal carcinoma and osteoclasts in an in vitro co-culture model. *J Bone Oncol*. 2019 Feb 27;16:100227. doi: 10.1016/j.jbo.2019.100227. eCollection 2019 Jun.
11. Bongiovanni A, Recine F, Fausti V, Foca F, Casadei R, Falasconi MC, Oboldi D, Sansoni E, Fabbri L, Micheletti S, Severi S, Matteucci F, Zavoiu V, Mercatali L, Amadori D, Ibrahim T. Ten-year experience of the multidisciplinary Osteoncology Center. *Support Care Cancer*. 2019 Sep;27(9):3395-3402. doi: 10.1007/s00520-019-4635-5.
12. Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, Spadazzi C, Miserocchi G, Recine F, Riva N, Nicolini S, Severi S, Martinelli G, Ibrahim T. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. *Dis Markers*. 2018 Dec 2;2018:6878409. doi: 10.1155/2018/6878409. eCollection 2018.
13. Bongiovanni A, Recine F, Foca F, Fausti V, Riva N, Fabbri G, Severi S, Liverani C, De Vita A, Spadazzi C, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age. *Endocr Connect*. 2018 Dec 1. pii: EC-18-0478.R1. doi: 10.1530/EC-18-0478.
14. Miserocchi G, De Vita A, Mercatali L, Recine F, Liverani C, Spadazzi C, Pieri F, Riva N, Bongiovanni A, Casadei R, Fausti V, Ibrahim T. Characterization and Drug Sensitivity of a New High-Grade Myxofibrosarcoma Cell Line. *Cells*. 2018 Oct 25;7(11). pii: E186. doi: 10.3390/cells7110186. IF 4.829
15. Mercatali L, Serra P, Miserocchi G, Spadazzi C, Liverani C, De Vita A, Marisi G, Bongiovanni A, Recine F, Pangan A, Masalu N, Ibrahim T, Amadori D. Dried Blood and Serum Spots As A Useful Tool for Sample Storage to Evaluate Cancer Biomarkers. *J Vis Exp*. 2018 Jun 11;(136). doi: 10.3791/57113. IF 1.184
16. De Vita A, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Recine F, Bongiovanni A, Pieri F, Cavaliere D, Fausti V, Amadori D, Ibrahim T. Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma. *J Vis Exp*. 2018 Apr 11;(134). doi: 10.3791/56767. IF 1.184
17. De Vita A, Recine F, Mercatali L, Miserocchi G, Liverani C, Spadazzi C, Casadei R, Bongiovanni A, Pieri F, Riva N, Amadori D, Ibrahim T. Myxofibrosarcoma primary cultures: molecular and pharmacological profile. *Ther Adv Med Oncol*. 2017 Dec;9(12):755-767. doi: 10.1177/1758834017737472. Epub 2017 Oct 28. IF 6.238
18. De Vita A, Recine F, Mercatali L, Miserocchi G, Spadazzi C, Liverani C, Bongiovanni A, Pieri F, Casadei R, Riva N, Fausti V, Amadori D, Ibrahim T. Primary Culture of Undifferentiated Pleomorphic Sarcoma: Molecular Characterization and Response to Anticancer Agents. *Int J Mol Sci*. 2017 Dec 8;18(12). pii: E2662. doi: 10.3390/ijms18122662. IF 3.6867
19. Bongiovanni A, Recine F, Celli M, Marcantognini G, Foca F, Liverani C, Fausti V, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Osteoblastic bone metastases from neuroendocrine tumor (NET) of unknown origin detected by 18fluorocholine PET/CT and its comparison with 68gallium-DOTATOC PET/CT: Case report

and review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(46):e8567. doi: 10.1097/MD.00000000000008567. Review. IF 2.028

20. Recine F, Bongiovanni A, Casadei R, Pieri F, Riva N, De Vita A, Mercatali L, Liverani C, Spadazzi C, Miserocchi G, Fausti V, Amadori D, Ibrahim T. Primary leiomyosarcoma of the bone: a case report and a review of the literature. *Medicine (Baltimore)*. 2017 Nov;96(45):e8545. doi: 10.1097/MD.00000000000008545. Review. IF 2.028
21. Miserocchi G, Mercatali L, Liverani C, De Vita A, Spadazzi C, Pieri F, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Management and potentialities of primary cancer cultures in preclinical and translational studies. *J Transl Med*. 2017 Nov 7;15(1):229. doi: 10.1186/s12967-017-1328-z. Review. IF 4.197
22. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines. *J Vis Exp*. 2017 Sep 13;(127). doi: 10.3791/56311. IF 1.184
23. Mercatali L, La Manna F, Miserocchi G, Liverani C, De Vita A, Spadazzi C, Bongiovanni A, Recine F, Amadori D, Ghetti M, Ibrahim T. Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition. *Int J Mol Sci*. 2017 Jul 29;18(8). pii: E1655. doi: 10.3390/ijms18081655. IF 3.687
24. Recine F, Bongiovanni A, Riva N, Fausti V, De Vita A, Mercatali L, Liverani C, Miserocchi G, Amadori D, Ibrahim T. Update on the role of trabectedin in the treatment of intractable soft tissue sarcomas. *Onco Targets Ther*. 2017 Feb 23;10:1155-1164. doi: 10.2147/OTT.S127955. eCollection 2017. Review. IF 2.656
25. Amadori D, Serra P, Masalu N, Pangan A, Scarpi E, Bugingo AM, Katabalo D, Ibrahim T, Bongiovanni A, Miserocchi G, Spadazzi C, Liverani C, Turri V, Tedaldi R, Mercatali L. Vitamin D receptor polymorphisms or serum levels as key drivers of breast cancer development? The question of the vitamin D pathway. *Oncotarget*. 2017 Feb 21;8(8):13142-13156. doi: 10.18632/oncotarget.14482. IF 5.008
26. Bongiovanni A, Recine F, Riva N, Foca F, Liverani C, Mercatali L, Nicolini S, Pieri F, Amadori D, Ibrahim T. Outcome Analysis of First-line Somatostatin Analog Treatment in Metastatic Pulmonary Neuroendocrine Tumors and Prognostic Significance of 18FDG-PET/CT. *Clin Lung Cancer*. 2017 Jul;18(4):415-420. doi: 10.1016/j.clcc.2016.11.004. Epub 2016 Nov 21
27. De Vita A, Miserocchi G, Recine F, Mercatali L, Pieri F, Medri L, Bongiovanni A, Cavaliere D, Liverani C, Spadazzi C, Amadori D, Ibrahim T. Activity of Eribulin in a Primary Culture of Well-Differentiated/Dedifferentiated Adipocytic Sarcoma. *Molecules*. 2016 Dec 3;21(12). Doi: 10.3390/molecules21121662 IF 2.861
28. Fici P, Gallerani G, Morel AP, Mercatali L, Ibrahim T, Scarpi E, Amadori D, Puisieux A, Rigaud M, Fabbri F. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer. *Oncotarget*. 2017 Jan 10;8(2):2423-2436. doi: 10.18632/oncotarget.13682. IF 5.008
29. Liverani C, La Manna F, Groenewoud A, Mercatali L, Van Der Pluijm G, Pieri F, Cavaliere D, De Vita A, Spadazzi C, Miserocchi G, Bongiovanni A, Recine F, Riva N, Amadori D, Tasciotti E, Snaar-Jagalska E, Ibrahim T. Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. *Biol Open*. 2017 Feb 15;6(2):133-140. doi: 10.1242/bio.022483. Erratum in: *Biol Open*. 2017 Feb 15;6(2):309. IF 2.095
30. Mercatali L, Spadazzi C, Miserocchi G, Liverani C, De Vita A, Bongiovanni A, Recine F, Amadori D, Ibrahim T. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts. *Int J Mol Sci*. 2016 Nov 1;17(11). Doi: 10.3390/ijms17111827 pii: E1827. IF 3.687
31. De Vita A, Mercatali L, Recine F, Pieri F, Riva N, Bongiovanni A, Liverani C, Spadazzi C, Miserocchi G, Amadori D, Ibrahim T. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas. *Onco Targets Ther*. 2016 Oct 11;9:6233-6246. Doi: 10.2147/OTT.S112580 eCollection 2016. Review. 2.612
32. Ibrahim T, Ricci M, Scarpi E, Bongiovanni A, Ricci R, Riva N, Liverani C, De Vita A, La Manna F, Oboldi D, Serra P, Foca F, Ceconetto L, Amadori D, Mercatali L. RANKL: A promising circulating marker for bone metastasis response. *Oncol Lett*. 2016 Oct;12(4):2970-2975. Doi: 10.3892/ol.2016.4977 Epub 2016 Aug 8. IF 1.390

33. Bongiovanni A, Monti M, Foca F, Recine F, Riva N, Di Iorio V, Liverani C, De Vita A, Miserocchi G, Mercatali L, Amadori D, Ibrahim T. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). *Support Care Cancer*. 2017 Jan;25(1):111-117. Doi: 10.1007/s00520-016-3390-0 Epub 2016 Aug 27. IF 2.698
34. Mercatali L, La Manna F, Groenewoud A, Casadei R, Recine F, Miserocchi G, Pieri F, Liverani C, Bongiovanni A, Spadazzi C, de Vita A, van der Pluijm G, Giorgini A, Biagini R, Amadori D, Ibrahim T, Snaar-Jagalska E. Development of a Patient-Derived Xenograft (PDX) of Breast Cancer Bone Metastasis in a Zebrafish Model. *Int J Mol Sci*. 2016 Aug 22;17(8). pii: E1375. doi: 10.3390/ijms17081375. IF3.226
35. Bongiovanni A, Riva N, Ricci M, Mercatali L, Liverani C, La Manna F, De Vita A, Cavaliere D, Pieri F, Oboldi D, Verdecchia GM, Amadori D, Ibrahim T. Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. *BMC Cancer*. 2015 Dec 22;15:998. doi: 10.1186/s12885-015-2038-7. IF 3.265
36. Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, Ibrahim T. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. *Onco Targets Ther*. 2015 Dec 3;8:3613-9. doi: 10.2147/OTT.S91971. eCollection 2015. IF 2.272
37. Bongiovanni A, Ricci M, Riva N, Calpona S, Oboldi D, Pieri F, Cavaliere D, Mercatali L, Liverani C, La Manna F, De Vita A, Foca F, Gunelli E, Amadori D, Ibrahim T. Pleural effusion in a patient with metastatic gastrointestinal stromal tumor treated with imatinib: case report. *Future Oncol*. 2014 Dec;10(15):2423-7. doi: 10.2217/fon.14.159. IF 2.447
38. Bongiovanni A, Riva N, Calpona S, Ricci M, Gunelli E, Liverani C, La Manna F, De Vita A, Monti M, Severi S, Pieri F, Amadori D, Galassi R, Cavaliere D, Zaccaroni A, Tartaglia A, Lunedei V, Gardini A, Mercatali L, Amadori D, Ibrahim T. Metronomic capecitabine in gastroenteropancreatic neuroendocrine tumors: a suitable regimen and review of the literature. *Onco Targets Ther*. 2014 Oct 20;7:1919-26. doi: 10.2147/OTT.S68573. eCollection 2014. IF 2.311
39. Ricci M, Amadori D, Chiesa F, Bongiovanni A, Liverani C, Fabbri L, Falasconi MC, Casadei R, Oboldi D, Galassi R, Micheletti S, Severi S, Serra L, Pieri F, Calabrese L, Riva N, Calpona S, Gunelli E, Mercatali L, Amadori D, Ibrahim T. Single bone metastasis from adenocarcinoma of the lacrimal gland: a case report. *Future Oncol*. 2014 Aug;10(10):1735-9. doi: 10.2217/fon.14.36. IF 2.611
40. Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, Tiede B, Romano RA, DeCoste C, Mercatali L, Ibrahim T, Amadori D, Kannan N, Eaves CJ, Sinha S, Kang Y. Δ Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. *Nat Cell Biol*. 2014 Oct;16(10):1004-15. doi: 10.1038/ncb3040. Epub 2014 Sep 21. IF 20.058
41. Ell B, Qiu Q, Wei Y, Mercatali L, Ibrahim T, Amadori D, Kang Y. The microRNA-23b/27b/24 cluster promotes breast cancer lung metastasis by targeting metastasis-suppressive gene prosaposin. *J Biol Chem*. 2014 Aug 8;289(32):21888-95. doi: 10.1074/jbc.M114.582866. Epub 2014 Jun 25. IF 4.6
42. Liverani C, Mercatali L, Spadazzi C, La Manna F, De Vita A, Riva N, Calpona S, Ricci M, Bongiovanni A, Gunelli E, Zanoni M, Fabbri F, Zoli W, Amadori D, Ibrahim T. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems. *Bone*. 2014 Sep;66:214-22. doi: 10.1016/j.bone.2014.06.017. IF 3.973
43. Ibrahim T, Mercatali L, Amadori D. A new emergency in oncology: Bone metastases in breast cancer patients (Review). *Oncol Lett*. 2013 Aug;6(2):306-310. Doi: 10.3892/ol.2013.1372 Epub 2013 Jun 4. IF 0.237
44. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, Amadori D, Kang Y. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. *Cancer Cell*. 2013 Oct 14;24(4):542-56. doi: 10.1016/j.ccr.2013.09.008. IF24.775
45. Ibrahim T, Mercatali L, Amadori D. Bone and cancer: the osteoncology. *Clin Cases Miner Bone Metab*. 2013 May;10(2):121-3. Review. IF
46. Amadori D, Mercatali L, Nanni O, Aglietta M, Alessi B, Gianni L, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI, Ibrahim T. What can we learn from the ZOOM trial?--Authors' reply. *Lancet Oncol*. 2013 Sep;14(10):e388-90. doi: 10.1016/S1470-2045(13)70295-X. IF 25.117

47. Mercatali L, Ricci M, Scarpi E, Serra P, Fabbri F, Ricci R, Liverani C, Zanoni M, Zoli W, Maltoni R, Gunelli E, Amadori D, Ibrahim T. RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study. *Int J Mol Sci.* 2013 May 23;14(6):10683-93. doi: 10.3390/ijms140610683. IF 2.464
48. Ibrahim T, Farolfi A, Mercatali L, Ricci M, Amadori D. Metastatic bone disease in the era of bone-targeted therapy: clinical impact. *Tumori.* 2013 Jan-Feb;99(1):1-9. doi: 10.1700/1248.13780. Review. IF 0.922
49. Ulivi P, Mercatali L, Casoni GL, Scarpi E, Bucchi L, Silvestrini R, Sanna S, Monteverde M, Amadori D, Poletti V, Zoli W. Multiple marker detection in peripheral blood for NSCLC diagnosis. *PLoS One.* 2013;8(2):e57401. doi: 10.1371/journal.pone.0057401. Epub 2013 Feb 26. IF 3.730
50. Ibrahim T, Liverani C, Mercatali L, Sacanna E, Zanoni M, Fabbri F, Zoli W, Amadori D. Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines. *Int J Oncol.* 2013 Apr;42(4):1263-70. doi: 10.3892/ijo.2013.1809. Epub 2013 Feb 6. IF 2.675
51. Zhang Y, Yang P, Sun T, Li D, Xu X, Rui Y, Li C, Chong M, Ibrahim T, Mercatali L, Amadori D, Lu X, Xie D, Li QJ, Wang XF. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. *Nat Cell Biol.* 2013 Mar;15(3):284-94. doi: 10.1038/ncb2690. Epub 2013 Feb 10. IF 20.761
52. Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, Ricci M, Nanni O, Serra L, Amadori D. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. *Oncology.* 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19.
53. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. *Cancer Cell Int.* 2012 Nov 22;12(1):48. doi: 10.1186/1475-2867-12-48. IF 1.971
54. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukačičin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. E1f5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. *Nat Cell Biol.* 2012 Nov;14(11):1212-22. doi: 10.1038/ncb2607. Epub 2012 Oct 21. IF 19.49
55. Korpál M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. *Nat Med.* 2011 Aug 7;17(9):1101-8. doi: 10.1038/nm.2401. IF 22.462
56. Ibrahim T, Sacanna E, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Ricci R, Serra L, Kang Y, Amadori D. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. *Clin Breast Cancer.* 2011 Dec;11(6):369-75. doi: 10.1016/j.clbc.2011.05.001. Epub 2011 Jul 20. IF 2.375
57. Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D. The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. *Oncology.* 2011;80(3-4):225-31. doi: 10.1159/000327585. Epub 2011 Jul 5.
58. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Bone metastases detection by circulating biomarkers: OPG and RANK-L. *Int J Oncol.* 2011 Jul;39(1):255-61. doi: 10.3892/ijo.2011.1001. Epub 2011 Apr 13.
59. Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer. *J Clin Pharmacol.* 2012 Mar;52(3):361-9. doi: 10.1177/0091270010396710. Epub 2011 Mar 7.
60. Casoni GL, Ulivi P, Mercatali L, Chilosi M, Tomassetti S, Romagnoli M, Ravaglia C, Gurioli C, Gurioli C, Zoli W, Silvestrini R, Poletti V. Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. *Int J Biol Markers.* 2010 Oct-Dec;25(4):229-35.

61. Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D. Pathogenesis of osteoblastic bone metastases from prostate cancer. *Cancer*. 2010 Mar 15;116(6):1406-18. doi: 10.1002/cncr.24896. Review. (Cit 87)
62. Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D. Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. *Tumori*. 2009 May-Jun;95(3):291-7.
63. Ulivi P, Mercatali L, Zoli W, Dell'amore D, Poletti V, Casoni GL, Scarpi E, Flamini E, Amadori D, Silvestrini R. Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. *Thorax*. 2008 Sep;63(9):843-4. doi: 10.1136/thx.2008.102178. No abstract available.
64. Ibrahim T, Barbanti F, Giorgio-Marrano G, Mercatali L, Ronconi S, Vicini C, Amadori D. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. *Oncologist*. 2008 Mar;13(3):330-6. doi: 10.1634/theoncologist.2007-0159.
65. Flamini E, Mercatali L, Nanni O, Calistri D, Nunziatini R, Zoli W, Rosetti P, Gardini N, Lattuneddu A, Verdecchia GM, Amadori D. *Clin Cancer Res*. 2006 Dec 1;12(23):6985-8. Doi: 10.1158/1078-0432.CCR-06-1931
66. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen*. 2003;41(5):315-21. Doi: 10.1002/em.10162
67. Mercatali L, Valenti V, Calistri D, Calpona S, Rosti G, Folli S, Gaudio M, Frassinetti GL, Amadori D, Flamini E. RT-PCR determination of maspin and mammaglobin B in peripheral blood of healthy donors and breast cancer patients. *Ann Oncol*. 2006 Mar;17(3):424-8. Epub 2005 Dec 15.
68. Santucci MA, Mercatali L, Brusa G, Pattacini L, Barbieri E, Perocco P. Cell-cycle deregulation in BALB/c 3T3 cells transformed by 1,2-dibromoethane and folpet pesticides. *Environ Mol Mutagen*. 2003;41(5):315-21.
69. Barbieri L, Brigotti M, Perocco P, Carnicelli D, Ciani M, Mercatali L, Stirpe F. Ribosome-inactivating proteins depurinate poly(ADP-ribosyl)ated poly(ADP-ribose) polymerase and have transforming activity for 3T3 fibroblasts. *FEBS Lett*. 2003 Mar 13;538(1-3):178-82.

NB: ai sensi della L. n. 196/03, si autorizza l'Ente/Società al trattamento dei dati personali qui riportati ai fini esclusivi legati alle collaborazioni professionali.